SetPFPGroupVar.htm
   
SetPProProdListVar.htm

New User? Register Now

Returning User? Sign In

Benefits of registering


login.htm

Visit other Pfizer sites
Search Medical Responses
View an extensive list of Pfizer sites
ppn-vr-sso-links.htm

Share Your Feedback
Product Centers | CAMPTOSAR® (irinotecan hydrochloride injection)
 
CAMPTOSAR(R) (irinotecan hydrochloride injection) Indication Statement CAMPTOSAR Injection is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum. CAMPTOSAR is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.

Dosing

CAMPTOSAR starting dose in combination with infusional 5-FU and LV

  • CAMPTOSAR 180 mg/m2 as 90-minute infusion

Dose modifications in combination therapy

Table of recommended dose modifications by event and therapeutic cycle

Toxicities were graded according to the National Cancer Institute Common Toxicity Criteria (version 1.0).
! Relative to the starting dose used in the previous cycle.
1 dose reduction level = 30 mg/m2 in an infusional regimen and 25 mg/m2 in a bolus regimen.
Excludes alopecia, anorexia, and asthenia.